Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study.
Lucas Tramujas, Alleh Nogueira, Nicole Felix...
https://pubmed.ncbi.nlm.nih.gov/39299823/Actively Recruiting
Led by Hospital do Coracao · Updated on 2026-01-22
7713
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are investigating the effects of a polypill combined with colchicine in people with established atherosclerotic cardiovascular disease ASCVD, a major cause of illness and death worldwide, including Brazil. The trial aims to assess whether this combination can better prevent heart and blood vessel events compared to usual care. The study addresses the need for improved control of cardiovascular risk factors and adherence to treatments in a diverse population. Participants will be randomly assigned to one of four groups cardiovascular polypill plus colchicine, cardiovascular polypill plus placebo, usual care plus colchicine, or usual care plus placebo. The polypill contains fixed doses of valsartan, atorvastatin, and aspirin, taken daily. Colchicine or its placebo is given once daily. The study will last about three years on average, with the goal of evaluating the combined effects of these treatments on cardiovascular health. During the study, participants will be monitored for major adverse cardiovascular and limb events, including heart attacks, strokes, and cardiovascular deaths. Researchers will collect data throughout the trial to assess treatment effects and safety. The study design includes a randomized, quadruple-masked approach to ensure unbiased results. Participants can expect regular evaluations over the study period, which ends around May 2031.
CONDITIONS
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital do Coracao
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - Up to approximately 3 years
Participants take a daily cardiovascular polypill and/or colchicine or placebo according to their assigned group to reduce cardiovascular risk.
Regular visits scheduled throughout treatment period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Lucas Tramujas, Alleh Nogueira, Nicole Felix...
https://pubmed.ncbi.nlm.nih.gov/39299823/Pedro G M de Barros E Silva, Charlene Troiani do Nascimento, Rodrigo Pinto Pedrosa...
https://pubmed.ncbi.nlm.nih.gov/38378735/Erlon Oliveira de Abreu-Silva, Martin Siepmann, Timo Siepmann
https://pubmed.ncbi.nlm.nih.gov/39336974/Lucas Tramujas, Alleh Nogueira, Nicole Felix...
https://pubmed.ncbi.nlm.nih.gov/40373935/Hospital do Coracao
Lead Sponsor